Ergoteles’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Ergoteles’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-57,279	Closed	-$85.9K	–	1707
2023 Q1	$85.9K	Buy	57,279 +12,129	+27%	+$16.3K	﹤0.01%	1112
2022 Q4	$45.1K	Sell	45,150 -65,519	-59%	-$88.3K	﹤0.01%	1305
2022 Q3	$199K	Sell	110,669 -36,731	-25%	-$107K	0.01%	1186
2022 Q2	$427K	Buy	+147,400	New	+$364K	0.01%	910
2021 Q4	–	Sell	-13,100	Closed	-$111K	–	1711
2021 Q3	$111K	Buy	+13,100	New	+$185K	﹤0.01%	1085

Ergoteles's TCRR Position: Q2 2023 in Review

Ergoteles sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 57,279 shares — an estimated $85.9K sold.

Ergoteles first reported a position in TCRR in Q3 2021 and held it in 5 quarters. The position peaked at $427K in Q2 2022. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Ergoteles reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 57,279 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $85.9K.
Ergoteles first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2021 and held it in 5 quarters.
Ergoteles's TCR2 Therapeutics Inc. Common Stock position peaked at $427K in Q2 2022.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.